A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options

• Published in: Science China. Life sciences Vol. 65; no. 9; pp. 1866 - 1880
• Main Authors: Liu, Yuntao, Song, Lan, Zheng, Nairen, Shi, Jinwen, Wu, Hongxing, Yang, Xing, Xue, Nianci, Chen, Xing, Li, Yimin, Sun, Changqing, Chen, Cha, Tang, Lijuan, Ni, Xiaotian, Wang, Yi, Shi, Yaling, Guo, Jianwen, Wang, Guangshun, Zhang, Zhongde, Qin, Jun
• Format: Journal Article
• Language: English
• Published: Beijing Science China Press 01.09.2022; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Coronaviruses; COVID-19; Inflammation; Life Sciences; Localization; Macrophages; Protein turnover; Proteomes; Proteomics; Research Paper; RNA viruses; Severe acute respiratory syndrome coronavirus 2; Signal transduction; Supplements; Therapeutic targets; Thrombolysis; Tricarboxylic acid cycle; COVID-19; itaconate; urine; CLYBL; proteome
• ISSN: 1674-7305; 1869-1889
• DOI: 10.1007/s11427-021-2070-y

Signaling pathway alterations in COVID-19 of living humans as well as therapeutic targets of the host proteins are not clear. We analyzed 317 urine proteomes, including 86 COVID-19, 55 pneumonia and 176 healthy controls, and identified specific RNA virus detector protein DDX58/RIG-I only in COVID-19 samples. Comparison of the COVID-19 urinary proteomes with controls revealed major pathway alterations in immunity, metabolism and protein localization. Biomarkers that may stratify severe symptoms from moderate ones suggested that macrophage induced inflammation and thrombolysis may play a critical role in worsening the disease. Hyper activation of the TCA cycle is evident and a macrophage enriched enzyme CLYBL is up regulated in COVID-19 patients. As CLYBL converts the immune modulatory TCA cycle metabolite itaconate through the citramalyl-CoA intermediate to acetyl-CoA, an increase in CLYBL may lead to the depletion of itaconate, limiting its anti-inflammatory function. These observations suggest that supplementation of itaconate and inhibition of CLYBL are possible therapeutic options for treating COVID-19, opening an avenue of modulating host defense as a means of combating SARS-CoV-2 viruses.